



## Foghorn Therapeutics to Participate at the William Blair Biotech Focus Conference 2021

Jul 9, 2021

CAMBRIDGE, Mass., July 09, 2021 (GLOBE NEWSWIRE) -- Foghorn Therapeutics Inc. (Nasdaq: FHTX), a company pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, today announced that Adrian Gottschalk, President & Chief Executive Officer, is scheduled to participate in a panel at the William Blair Biotech Focus Conference 2021, which is being held virtually from July 14-15.

### **Panel Details:**

**Title:** Next Generation Small Molecules in Oncology

**Panel date and time:** Thursday, July 15, 9:00 a.m. ET

A live webcast of the panel can be accessed under "Events & Presentations" in the Investors section of the Company's website, [www.foghornrx.com](http://www.foghornrx.com).

### **About Foghorn Therapeutics**

Foghorn® Therapeutics is discovering and developing a novel class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Through its proprietary scalable Gene Traffic Control® platform, Foghorn is systematically studying, identifying and validating potential drug targets within the chromatin regulatory system. The company is developing multiple product candidates in oncology.

### **Media Contact:**

Fanny Cavalié, Foghorn Therapeutics  
[fcavalié@foghornrx.com](mailto:fcavalié@foghornrx.com)

Gregory Kelley, Ogilvy  
[gregory.kelley@ogilvy.com](mailto:gregory.kelley@ogilvy.com)

### **Investor Relations Contact:**

Allan Reine, Foghorn Therapeutics  
[areine@foghornrx.com](mailto:areine@foghornrx.com)

Hans Vitzthun, LifeSci Advisors  
617-430-7578  
[hans@lifesciadvisors.com](mailto:hans@lifesciadvisors.com)